Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: A comparison with ESHAP

Transfusion

Volumn 47, Issue 8, 2007, Pages 1447-1454

  Kim, Min Kyoung ^a   Kim, Shin ^a   Lee, Sung Sook ^a   Sym, Sun Jin ^a   Lee, Dae Ho ^a   Kim, Sang We ^a   Jang, Seongsoo ^a   Park, Chan Jeong ^a   Chi, Hyun Sook ^a   Huh, Jooryung ^a   Suh, Cheolwon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHYLPREDNISOLONE; PARACETAMOL; PHENIRAMINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BACTEREMIA; BLOOD SAMPLING; BRONCHOSPASM; CELLULITIS; CHILL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOPOIETIC STEM CELL; HERPES ZOSTER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; OVERALL SURVIVAL; PNEUMONIA; THROMBOCYTE COUNT; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA, B-CELL; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547133235     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01285.x     Document Type: Article

References (37)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995 333 : 1540 5.
2. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976 47 : 1031 9.
3. McQuaker IG, Haynes AP, Stainer C, Anderson S, Russell NH. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol 1997 98 : 228 33.
4. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999 17 : 3776 85.
5. Lee JL, Kim S, Kim SW, et al. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005 35 : 449 54.
6. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999 17 : 268 76.
7. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 346 : 235 42.
8. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001 19 : 389 97.
9. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004 103 : 3684 8.
10. Flohr T, Hess G, Kolbe K, et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002 29 : 769 75.
11. Endo T, Sato N, Mogi Y, et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004 33 : 703 7.
12. Lazzarino M, Arcaini L, Bernasconi P, et al. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002 116 : 229 35.
13. Belhadj K, Delfau-Larue MH, Elgnaoui T, et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single-institution study. Ann Oncol 2004 15 : 504 10.
14. Hess G, Flohr T, Kolbe K, et al. Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma. Ann Hematol 2006 85 : 769 79.
15. Benekli M, Hahn T, Shafi F, et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 2003 32 : 139 43.
16. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001 98 : 579 85.
17. Holtan SG, Porrata LF, Inwards DJ, et al. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. Br J Haematol 2006 133 : 628 33.
18. Suh C, Kim S, Kim SH, et al. Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000. Transfusion 2004 44 : 1762 8.
19. Yu J, Leisenring W, Fritschle W, et al. Enumeration of HPC in mobilized peripheral blood with the Sysmex SE9500 predicts final CD34+ cell yield in the apheresis collection. Bone Marrow Transplant 2000 25 : 1157 64.
20. Park KU, Kim SH, Suh C, et al. Correlation of hematopoietic progenitor cell count determined by the SE-automated hematology analyzer with CD34(+) cell count by flow cytometry in leukapheresis products. Am J Hematol 2001 67 : 42 7.
21. Lee JL, Kim SB, Lee GW, et al. Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest. J Korean Med Sci 2003 18 : 27 35.
22. Choi CW, Paek CW, Seo JH, et al. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma. J Korean Med Sci 2002 17 : 621 4.
23. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens: the M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 1997 11 : 937 47.
24. Jermann M, Jost LM, Taverna CH, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004 15 : 511 6.
25. Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 2006 24 : 593 600.
26. Jansen J, Falkenburg JH, Stepan DE, LeBien TW. Removal of neoplastic cells from autologous bone marrow grafts with monoclonal antibodies. Semin Hematol 1984 21 : 164 81.
27. Jacquy C, Soree A, Lambert F, et al. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 2000 110 : 631 7.
28. Berenson RJ, Bensinger WI, Hill RS, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991 77 : 1717 22.
29. van Heeckeren WJ, Vollweiler J, Fu P, et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol 2006 132 : 42 55.
30. Hoerr AL, Gao F, Hidalgo J, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004 22 : 4561 6.
31. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998 92 : 1471 90.
32. Pedrazzini A, Freedman AS, Andersen J, et al. Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. Blood 1989 74 : 2203 11.
33. Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte counts and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004 33 : 291 8.
34. Kim H, Sohn HJ, Kim SE, et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004 34 : 43 9.
35. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003 101 : 391 8.
36. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002 20 : 2453 63.
37. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005 106 : 2896 902.